Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | USP2 | O75604 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.59 |
| ▸ | IDO1 | P14902 | 1/20 | 0.59 |
| ▸ | HAT1 | O14929 | 4/20 | 0.52 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.52 |
| ▸ | RECQL | P46063 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.52 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.52 |
| ▸ | CASP7 | P55210 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TST | Q16762 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12958653 | 0.94 | MEN1 (0.55) | MEN1KMT2AKDM4EUSP2HTT | |
| SCHEMBL12958643 | 0.94 | MEN1 (0.57) | MEN1KMT2AKDM4EUSP2HTT | |
| SCHEMBL864749 | 0.93 | MEN1 (0.52) | MEN1KMT2AKDM4EUSP2HTT | |
| Trifluoroacetic Acid SCHEMBL864102 | 0.93 | MEN1 (0.56) | MEN1KMT2AKDM4EUSP2HTT | |
| SCHEMBL10251990 | 0.92 | MEN1 (0.57) | MEN1KMT2AKDM4EUSP2HTT | |
| SCHEMBL10252166 | 0.92 | KMT2A (0.59) | MEN1KMT2AKDM4EUSP2HTT | |
| Hydrochloric Acid SCHEMBL863762 | 0.91 | MEN1 (0.56) | MEN1KMT2AKDM4EUSP2HTT | |
| Hydrochloric Acid SCHEMBL865034 | 0.91 | KMT2A (0.58) | MEN1KMT2AKDM4EUSP2HTT | |
| SCHEMBL12958976 | 0.91 | KMT2A (0.58) | MEN1KMT2AKDM4EUSP2HTT | |
| SCHEMBL10252091 | 0.90 | MEN1 (0.55) | MEN1KMT2AKDM4EUSP2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130129695-A1 | METHODS FOR TREATING OR INHIBITING INFECTION BY CLOSTRIDIUM DIFFICILE | BLOUNT KENNETH (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129695-A1 | METHODS FOR TREATING OR INHIBITING INFECTION BY CLOSTRIDIUM DIFFICILE | BLOUNT KENNETH (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013040412-A2 | METHODS FOR INHIBITING BACTERIA GROWTH | BIORELIX, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2448926-A1 | FLAVIN DERIVATIVES | Biorelix, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| EP-2320734-A1 | FLAVIN DERIVATIVES | BioRelix, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2011008247-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008247-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130129695-A1 | METHODS FOR TREATING OR INHIBITING INFECTION BY CLOSTRIDIUM DIFFICILE | TRDMT1, TRMT1, TRMT1L | MEN1 4795/4885KMT2A 1446/4885KDM4E 1028/4885 |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | MEN1 4416/4885KMT2A 3259/4885KDM4E 1942/4885 |
| US-20120077781-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | MEN1 4416/4885KMT2A 3259/4885KDM4E 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.